Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cardioblate BP in Europe

This article was originally published in The Gray Sheet

Executive Summary

Medtronic surgical ablation system earns CE mark for treatment of atrial fibrillation, company announces during European Association of Thoracic Surgeons sessions Oct. 14 in Vienna. The system features a transmurality feedback mechanism that alerts surgeons when the ablation line passes all the way through the tissue, the company notes. Medtronic earned FDA clearance for the device in February 2002 and plans to complete a trial in support of an AF indication in 2004 (1"The Gray Sheet" Aug. 11, 2003, In Brief)...

You may also be interested in...

Medtronic next-gen Cardioblate BP cleared by FDA

Firm plans to commence a clinical trial to examine device effectiveness in treating chronic atrial fibrillation this autumn, Medtronic states Aug. 6, following July clearance of the bipolar radiofrequency ablation system for surgical procedures. The more specific indication, for which the firm plans to seek agency go-ahead, following trial completion in 2004, would allow Medtronic to market the device specifically for AF. The single-electrode, first-generation device was first cleared in February 2002 (1'The Gray Sheet" Feb. 4, 2002, In Brief)...

Dr Reddy's Adds To OTC Portfolio With Glenmark Deal

Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from fellow Indian firm Glenmark.

Sandoz Launches US Awareness Campaign

Sandoz has launched an awareness campaign under the banner of “Ask For Generics” in the US. The initiative is aiming to educate stakeholders on the benefits of generics and their quality, safety and efficacy.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts